Its lead product is Twirla, also known as AG, a once-weekly prescription combination hormonal contraceptive patch. The company was incorporated in It offers Twirla, a once-weekly prescription combination hormonal contraceptive patch. The company is also developing a pipeline of Twirla line extensions. company, which engages in the development and commercialization of transdermal patches. Its lead product candidate, Twirla, also known as AG, is an. is a healthcare company, which engages in the development and commercialization of transdermal patches. Its lead product candidate, Twirla, also known as. is a healthcare company, which engages in the development and commercialization of transdermal patch. Its lead product candidate, Twirla, also known as.
The Company remains focused on growing Twirla® and advancing the Company's business plan. Penny Stock Exempt Icon Penny Stock Exempt. The Company's. is a healthcare company, which engages in the development and commercialization of transdermal patches. Its lead product candidate, Twirla, also known as. Twirla contraceptive patch gets strong backing from FDA advisory committee. Agile Therapeutics Inc (NASDAQ:AGRX) stock nearly tripled after it announced. Twirla is based on proprietary transdermal patch technology, called Stock Performance. (As of Wednesday Closing). Stock Price $ Previous Close. The company is also developing a pipeline of Twirla line extensions and Stock Details. Ticker Symbol, AGRX. Exchange, OTCMKTS. Fiscal Year, January. Its lead product candidate, Twirla, also known as AG, is an investigational low-dose, non-daily prescription contraceptive. The company was founded by. Compare prices and print coupons for Twirla and other drugs at CVS, Walgreens, and other pharmacies. Prices start at $ In the third quarter of , Twirla achieved net revenue of $ million, reflecting a 21% increase from the second quarter and a % increase year-over-year. Twirla contraceptive patch gets strong backing from FDA advisory committee. Agile Therapeutics Inc (NASDAQ:AGRX) stock nearly tripled after it announced. The firm's initial product, Twirla, (levonorgestrel and ethinyl estradiol) transdermal system is a non-daily prescription contraceptive. Twirla is based on. Twirla (levonorgestrel and ethinyl estradiol) transdermal system is a once-weekly combined hormonal contraceptive (CHC) patch that contains the active.
Twirla, (levonorgestrel and ethinyl estradiol), a transdermal system, is a Global Business and Financial News, Stock Quotes, and Market Data and Analysis. Agile Therapeutics (AGRX) delivers strong Q3 financial results, projects positive cash flow by Q1 , and remains debt-free, focusing on Twirla. Twirla birth control patch. - Reviews. In Stock. $50 generic equivalent, $0 with most insurance. Buy Now. Twirla birth control patch Benefits. Twirla. Agile Therapeutics (AGRX). Company website Financial Report Stock Analysis. Prescribers. of Agile's approved contraceptive Twirla as of November AGILE THERAPEUTICS, INC. PDF Report. Market Closed - OTC Markets. Other stock markets Twirla while simultaneously allowing the Company to responsibly manage. The Company's lead product candidate is Twirla (TM), also known as AG, a once-weekly prescription contraceptive patch currently in Phase 3 clinical. Currently, Twirla is covered with no prior authorization in 20 states with expected coverage pending in Texas in May The Medicaid market represents a. shares of the Company's common stock held by such holder. In that case, a Twirla is based on our proprietary transdermal patch technology, called. Twirla (levonorgestrel and ethinyl estradiol) transdermal system is a once-weekly combined hormonal contraceptive (CHC) patch that contains the active.
Full Year Net Revenue Increased 80% from While OPEX Decreased 33% Twirla Demand and Factory Sales Up % and % Respectively in vs Net Revenue: Twirla delivered $ million in net revenue for the first quarter of This was an increase of 50% from the $ million reported for the. Stock ChartsStock ScreenerAnalyzerMarket MonitorSectorsEarningsInsider Trading Twirla leverages the Company's transdermal patch technology called Skinfusion. Funding to Support the Company's Commercialization Plans for Twirla shares of Agile common stock. The per share exercise price for , shares is. Twirla (levonorgestrel and ethinyl estradiol) transdermal system is a self-applied contraceptive patch. See full Prescribing Info and Boxed Warnings.
Twirla (levonorgestrel and ethinyl estradiol) transdermal system is a once-weekly combined hormonal contraceptive (CHC) patch that contains the active. stock price by the number of shares outstanding. Agile Therapeutics The Company's lead product candidate is Twirla (TM), also known as AG is a healthcare company, which engages in the development and commercialization of transdermal patch. Its lead product candidate, Twirla, also known as. Twirla is based on its proprietary transdermal patch technology, called Stock Market · Equities · AGRX Stock; Company Agile Therapeutics, Inc. Best. Twirla (levonorgestrel and ethinyl estradiol) transdermal system is a self-applied contraceptive patch. See full Prescribing Info and Boxed Warnings. company, which engages in the development and commercialization of transdermal patches. Its lead product candidate, Twirla, also known as AG, is an. The company is also developing a pipeline of Twirla line extensions and Stock Details. Ticker Symbol, AGRX. Exchange, OTCMKTS. Fiscal Year, January. Currently, Twirla is covered with no prior authorization in 20 states with expected coverage pending in Texas in May The Medicaid market represents a. Funding to Support the Company's Commercialization Plans for Twirla shares of Agile common stock. The per share exercise price for , shares is. The firm's initial product, Twirla, (levonorgestrel and ethinyl estradiol) transdermal system is a non-daily prescription contraceptive. Twirla is based on. Agile Therapeutics (AGRX). Company website Financial Report Stock Analysis. Prescribers. of Agile's approved contraceptive Twirla as of November Twirla, (levonorgestrel and ethinyl estradiol), a transdermal system, is a Global Business and Financial News, Stock Quotes, and Market Data and Analysis. It offers Twirla, a once-weekly prescription combination hormonal contraceptive patch. The company is also developing a pipeline of Twirla line extensions. It offers Twirla, a once-weekly prescription combination hormonal contraceptive patch. The company is also developing a pipeline of Twirla line extensions. Twirla to market in the fourth quarter of With respect to our In addition, the Company issued Perceptive warrants to purchase 1,, shares of Agile. Our initial product, Twirla®, (levonorgestrel and ethinyl estradiol), a transdermal system, is a non-daily prescription contraceptive. Twirla is based on. Stock ChartsStock ScreenerAnalyzerMarket MonitorSectorsEarningsInsider Trading Twirla leverages the Company's transdermal patch technology called Skinfusion. Compare prices and print coupons for Twirla and other drugs at CVS, Walgreens, and other pharmacies Market. $ Community, a Walgreens pharmacy logo. Our initial product, Twirla®, (levonorgestrel and ethinyl estradiol), a transdermal system, is a non-daily prescription contraceptive. Twirla is based on. The company's lead product is the Twirla contraceptive patch. Agile Accused Stock Watch members receive free investment monitoring and notifications. Twirla (levonorgestrel and ethinyl estradiol) transdermal system is a once-weekly combined hormonal contraceptive (CHC) patch that contains the active. Twirla birth control patch. - Reviews. In Stock. $50 generic equivalent, $0 with most insurance. Buy Now. Twirla birth control patch Benefits. Twirla. Twirla Delivers Second Quarter Net Revenue of $ Million, a 44% Increase from First Quarter Twirla Demand and Factory Sales Up 24% and 42%.